Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation-Reference-Cited by-同舟云学术

Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Published:2021-05 Issue:5 Volume:27 Page:405.e1-405.e6
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Liang Emily C.,Muffly Lori S.,Shiraz Parveen,Shizuru Judith A.,Johnston Laura,Arai Sally,Frank Matthew J.,Weng Wen-Kai,Lowsky Robert,Rezvani Andrew,Meyer Everett H.,Negrin Robert,Miklos David B.,Sidana Surbhi

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference45 articles.

1. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med,2017

2. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial;Voorhees;Blood,2020

3. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;Benboubker;N Engl Med,2014

4. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management;Rajkumar;Am. Hematol,2018

5. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE [e-pub ahead of print July 21, 2020];Goldschmidt;Leukemia,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project;Journal of Clinical Apheresis;2024-05-27

2. Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost;Current Stem Cell Research & Therapy;2024-04-03

3. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations;Blood;2023-09-07

4. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy;Transplantation and Cellular Therapy;2023-09

5. Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience;Bone Marrow Transplantation;2023-07-21